UNSPSC 51111783: Brentuximab vedotin

Brentuximab vedotin is an antibody-drug conjugate medication used to treat relapsed or refractory Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (ALCL).

UNSPSC 51111783 Brentuximab vedotin, a Commodity code, shows minimal relevant recent state and local procurement activity. The code nominally refers to a specific oncology therapeutic agent, but the recent opportunities block contains no bids, RFPs, RFQs, or ITBs for this drug or its pharmaceutical equivalents. The block includes one notice of office relocation (Williamson County Purchasing Department), multiple vendor networking events and trade shows (Marion County Reverse Trade Show, Central Florida NIGP Reverse Trade Show, Collin County Governmental Purchasers Forum, Pasco County How to Do Business Event, and FAPPO Annual Trade Show), one vendor feedback survey (City of Richardson), and several solicitations for unrelated services including emergency medical supplies (Seminole County naloxone and drug deactivation systems), BLS/ALS pharmaceuticals and vending machines (City of Tucson Fire Department), forensic drug standards (Pinellas County), clinic and wellness services (Collier County), engineering services (Orange County), pharmacy benefits programs (District of Columbia), medical oxygen rentals (City of Little Rock), peer support services (San Mateo County), and multistate cooperative purchasing for generic pharmaceuticals and OTC products (Minnesota MMCAP).

None of these opportunities target brentuximab vedotin specifically or the class of monoclonal antibody immunotherapies for lymphoma and other hematologic malignancies. The multistate cooperative procurement for generic multi-source pharmaceuticals and OTC products (S1070000015802, Minnesota MMCAP, RFP, response due March 26, 2026) represents the only pharmaceutical supply chain activity in the block, but it addresses commodity generics and over-the-counter items distributed through traditional wholesalers—a different market segment from specialty oncology biologics. No state health departments, Medicaid programs, cancer centers, or oncology pharmacy networks appear in the recent opportunities. The code shows no detectable recent procurement momentum at the state or local level.